Pre­vail grabs $75M A round in the hunt for new gene ther­a­pies to stop the de­struc­tion caused by Parkin­son's

An­oth­er biotech up­start is com­ing along to com­pete in the fast-grow­ing are­na of gene ther­a­py de­vel­op­ment for neu­rode­gen­er­a­tive dis­eases.

Just a cou­ple of weeks af­ter Ab­b­Vie tied up with Voy­ager on a gene ther­a­py pro­gram for Alzheimer’s, Pre­vail Ther­a­peu­tics is de­but­ing to­day with a $75 mil­lion A round and a mis­sion to go af­ter a dis­ease-mod­i­fy­ing ap­proach to Parkin­son’s dis­ease. The biotech was seed­ed by Or­biMed and the Sil­ver­stein Foun­da­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER